| Listing Date | 23rd October, 2026 |
| BSE Code | 545001 |
| NSE Code | SMT |
| ISIN Code | INE356Y01018 |
| Offer Price | ₹327 to ₹344 |
| Face Value | ₹1 |
| Listing Price | ₹371.15 |
Details About Sahajanand Medical Technologies IPO
Sahajanand Medical Technologies received SEBI approval for a ₹475.5 crore IPO, via an offer for sale of up to 1,38,22,116 equity shares with a face value of ₹1 each. Sahajanand Medical Technologies IPO price band is ₹327 to ₹344 per share.
Retail Individual Investors (RII):
- Minimum application: 1 lot = 43 shares
- Maximum application: 13 lots = 559 shares
Small High Net-worth Individuals (S-HNI):
- Minimum application: 14 lots = 602 shares
- Maximum application: 67 lots = 2881 shares
- B-HNI Minimum: 68 lots = 2924 shares
To invest in the Sahajanand Medical Technologies IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum investment of ₹14,792.
- Retail investors’ (Max) investment: ₹1,92,296.
- Small HNI (S-HNI): Minimum investment of ₹2,07,088.
- Small HNI (S-HNI): Maximum investment of ₹9,91,064.
- B-HNI: Minimum investment of ₹10,05,856.
Sahajanand Medical Technologies subscription duration
Sahajanand Medical Technologies IPO started on October 15, 2026, and closed on October 19, 2026. The investors’ allotment date was October 21, 2026, and they received a refund on October 22, 2026. The Sahajanand Medical Technologies IPO listing date is October 23, 2026.
About Sahajanand Medical Technologies Company
Sahajanand Medical Technologies, Founded in 2001, is one of the leading medical device firms that focuses on Class III and Class C/D devices, mainly working in the fields of vascular and structural heart intervention. The company was the first globally to achieve CE certification for a drug-eluting stent (DES) with a biodegradable polymer, Infinnium.
Its product range is divided into 3 main categories: Vascular Intervention (VI), Structural Heart (SH), and other products. Sahajanand operates two R&D centers, one in India & one in Thailand, backed by a team of 102 professionals such as biomedical engineers and clinical research specialists.